Industries > Pharma > Global Oncology Pricing, Reimbursement & Market Access 2019-2029

Global Oncology Pricing, Reimbursement & Market Access 2019-2029

US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China

PUBLISHED: 10 September 2019
PAGES: 292
PRODUCT CODE: PHA0522
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0522 Categories: , Tags: , , , ,

The global oncology pricing, reimbursement and market access report provides analysis and evaluation of the current and prospective economic burden of cancer treatment in the US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China. This report also outlines historical and current healthcare status for the selected markets with respect to expenditures along with the healthcare system that governs medical access.

In this report, we provide comprehensive view on some of the trends for top-seller oncology drugs including payer’s perspective on cancer outcomes, impact of these high cost drugs, standard guidelines preferred for different cancers, availability and costs of oncology therapeutics and complexity in cancer treatments as well as epidemiology of different cancer types.

How this report will benefit you
In this brand new 292-page report you will receive 98 charts– all unavailable elsewhere.

The 292-page report provides clear detailed insight into the global oncology pricing, reimbursement & market access. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Key questions answered by this report:
• Factors Affecting Pricing and Reimbursement Decision
• Pricing Negotiations and Discounts
• Reimbursement Policies
• Role of HEOR and Economic Value Planning
• Drug Patent Expiry and Effects on Pricing
• Cost-Effectiveness Analysis

• This report discusses healthcare system, pricing & reimbursement process, HTA, oncology cost of treatment, payer insights, healthcare expenditure, health coverage, key formularies, role of pharmacists, regulatory & approval process for these countries:
• United States
• Canada
• Germany
• France
• UK
• Italy
• Spain
• Japan
• Australia
• Brazil
• Russia
• India
• China

• Discussion on parallel import and its impact in the US and Europe.

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Oncology Pricing, Reimbursement and Market Access. You find data, trends and predictions.

Buy our report today Global Oncology Pricing, Reimbursement & Market Access 2019-2029: US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Oncology Pricing, Reimbursement & Market Access 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Oncology Pricing, Reimbursement & Market Access 2019-2029


Latest Pharma news

Visiongain Publishes Top 50 Pharmaceutical Wholesale & Distribution Companies 2021

Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

04 August 2021

READ

Visiongain Publishes 3D Printing for Healthcare Market Report 2021-2031

The growing use of this technology in many applications such as transplantation, drug delivery, 3D printed organs, and many others in the healthcare industry is one of the key drivers in the global 3D Printing in Healthcare Market.

02 August 2021

READ

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Categories